![Aclaris Therapeutics Inc](/common/images/company/N_ACRS.png)
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from... Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. 더 보기
WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for...
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 2.5 | 2.61 | 2.33 | 1109738 | 2.47952135 | CS |
4 | 0.09 | 3.73443983402 | 2.41 | 2.639999 | 2.28 | 975661 | 2.48819562 | CS |
12 | 0.32 | 14.6788990826 | 2.18 | 5.17 | 2.03 | 2665998 | 3.70827661 | CS |
26 | 1.22 | 95.3125 | 1.28 | 5.17 | 1.12 | 1466459 | 3.27334536 | CS |
52 | 1.38 | 123.214285714 | 1.12 | 5.17 | 0.9515 | 1219576 | 2.44922326 | CS |
156 | -8.73 | -77.7382012467 | 11.23 | 18.9583 | 0.5902 | 1187534 | 4.50654777 | CS |
260 | 1.17 | 87.969924812 | 1.33 | 30.375 | 0.5902 | 1048402 | 7.5339545 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관